Free Trial

Organon & Co. (OGN) Competitors

Organon & Co. logo
$9.46 -0.18 (-1.87%)
Closing price 03:59 PM Eastern
Extended Trading
$9.47 +0.01 (+0.10%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OGN vs. BPMC, BBIO, VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, and NUVL

Should you be buying Organon & Co. stock or one of its competitors? The main competitors of Organon & Co. include Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

Organon & Co. vs. Its Competitors

Blueprint Medicines (NASDAQ:BPMC) and Organon & Co. (NYSE:OGN) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Organon & Co. has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$508.82M16.43-$67.09M-$2.47-52.42
Organon & Co.$6.40B0.38$864M$2.883.28

Blueprint Medicines presently has a consensus target price of $128.25, suggesting a potential downside of 0.95%. Organon & Co. has a consensus target price of $18.00, suggesting a potential upside of 90.27%. Given Organon & Co.'s stronger consensus rating and higher probable upside, analysts clearly believe Organon & Co. is more favorable than Blueprint Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Blueprint Medicines
0 Sell rating(s)
17 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.24
Organon & Co.
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.50

In the previous week, Organon & Co. had 50 more articles in the media than Blueprint Medicines. MarketBeat recorded 58 mentions for Organon & Co. and 8 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 1.15 beat Organon & Co.'s score of 0.27 indicating that Blueprint Medicines is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Blueprint Medicines
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Organon & Co.
8 Very Positive mention(s)
1 Positive mention(s)
42 Neutral mention(s)
4 Negative mention(s)
3 Very Negative mention(s)
Neutral

Blueprint Medicines has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.

77.4% of Organon & Co. shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by insiders. Comparatively, 2.0% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Organon & Co. has a net margin of 11.92% compared to Blueprint Medicines' net margin of -27.70%. Organon & Co.'s return on equity of 227.43% beat Blueprint Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Blueprint Medicines-27.70% -64.60% -17.22%
Organon & Co. 11.92%227.43%7.34%

Summary

Organon & Co. beats Blueprint Medicines on 11 of the 16 factors compared between the two stocks.

Get Organon & Co. News Delivered to You Automatically

Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OGN vs. The Competition

MetricOrganon & Co.Medical Services IndustryMedical SectorNYSE Exchange
Market Cap$2.51B$6.98B$5.54B$20.85B
Dividend Yield0.83%2.88%3.75%3.65%
P/E Ratio3.2826.7928.0127.55
Price / Sales0.3836.65433.8159.20
Price / Cash1.9628.0836.1622.29
Price / Book5.179.018.124.66
Net Income$864M$233.10M$3.25B$994.58M
7 Day Performance-4.83%-0.15%0.97%-0.29%
1 Month Performance-4.31%1.22%7.36%4.91%
1 Year Performance-54.90%23.83%31.31%10.53%

Organon & Co. Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OGN
Organon & Co.
4.8555 of 5 stars
$9.46
-1.9%
$18.00
+90.3%
-54.4%$2.51B$6.40B3.284,000Trending News
BPMC
Blueprint Medicines
1.0758 of 5 stars
$128.40
+0.0%
$128.06
-0.3%
+13.2%$8.29B$508.82M-51.98640News Coverage
Positive News
BBIO
BridgeBio Pharma
4.6238 of 5 stars
$43.50
-1.1%
$58.85
+35.3%
+67.0%$8.26B$221.90M-12.32400Analyst Revision
VRNA
Verona Pharma PLC American Depositary Share
2.2988 of 5 stars
$91.20
-0.4%
$107.36
+17.7%
+358.8%$7.76B$42.28M-45.6030
ROIV
Roivant Sciences
2.6714 of 5 stars
$10.74
-2.3%
$17.50
+62.9%
+3.6%$7.30B$29.05M-42.96860Positive News
ELAN
Elanco Animal Health
1.8068 of 5 stars
$14.48
-1.1%
$15.33
+5.9%
+14.6%$7.19B$4.44B19.579,000Analyst Upgrade
Analyst Revision
RVMD
Revolution Medicines
4.5503 of 5 stars
$36.67
-3.2%
$67.58
+84.3%
-15.9%$6.83B$11.58M-9.17250Analyst Forecast
LEGN
Legend Biotech
3.5835 of 5 stars
$35.87
+0.6%
$72.60
+102.4%
-23.4%$6.59B$728.30M-60.802,609News Coverage
Positive News
Analyst Forecast
Analyst Revision
GRFS
Grifols
3.8994 of 5 stars
$8.87
-2.3%
$10.30
+16.1%
+24.7%$6.10B$7.81B7.5823,822News Coverage
TGTX
TG Therapeutics
3.4049 of 5 stars
$35.98
-2.0%
$40.80
+13.4%
+77.5%$5.71B$329M149.92290
NUVL
Nuvalent
3.1882 of 5 stars
$77.93
-3.2%
$119.60
+53.5%
+6.4%$5.60BN/A-17.7540Insider Trade

Related Companies and Tools


This page (NYSE:OGN) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners